Citi analyst Patrick Donnelly lowered the firm’s price target on Medline (MDLN) to $55 from $60 and keeps a Buy rating on the shares. The firm reduced estimates post the Q1 report to reflect higher input costs.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- Medline Maintained at Buy as Analyst Trims Price Target to $53 on Margin Pressures but Highlights Strong Growth Outlook
- Medline reports Q1 adjusted EPS 33c, consensus 29c
- Medline backs FY26 adjusted EBITDA view $3.5B-$3.6B
- Medline issued recall of all neuro sponge products, FDA says
- Medline share weakness overdone, ‘misinterpretation’-driven, says Leerink